Safety and efficacy of venom immunotherapy: a real life study

Postȩpy dermatologii i alergologii
Agnieszka KołaczekMaciej Kupczyk

Abstract

Venom immunotherapy (VIT) is recommended as the first-line treatment for patients allergic to Hymenoptera venom. To analyze the safety and efficacy of VIT in a real life setting. One hundred and eighty patients undergoing VIT were studied to evaluate the safety, efficacy, incidence and nature of symptoms after field stings and adverse reactions to VIT. Significantly more patients were allergic to wasp than bee venom (146 vs. 34, p < 0.0001). Early and late side effects were more common during the maintenance (48 patients, 26.7%) than during the induction of VIT (32 patients, 17.8%), were more frequent in patients allergic to bees, and were not associated with angiotensin convertase inhibitors (ACEi) or β-adrenergic antagonists use. Systemic reactions were observed in 4 individuals on wasp VIT (2.7%) and in 6 patients allergic to bees (17.65%). The VIT was efficacious as most patients reported no reactions (50%) or reported only mild local reactions (43.75%) to field stings. The decrease in sIgE at completion of VIT correlated with the dose of vaccine received (r = 0.53, p = 0.004). Beekeeping (RR = 29.54, p < 0.0001) and female sex (RR = 1.27, p = 0.033) were associated with a higher risk of venom allergy. Venom immunotherapy i...Continue Reading

Citations

Oct 9, 2019·Allergy·Urban ČerpesGunter J Sturm
Aug 28, 2020·Frontiers in Pharmacology·Karla de Castro Figueiredo BordonEliane Candiani Arantes
Nov 7, 2017·Human Vaccines & Immunotherapeutics·Andrzej Bożek, Krzysztof Kołodziejczyk
Aug 28, 2021·International Journal of Molecular Sciences·Marta Burzyńska, Dorota Piasecka-Kwiatkowska
Aug 2, 2021·The Journal of Allergy and Clinical Immunology. in Practice·Christopher M WarrenRuchi S Gupta
Jan 3, 2020·Complementary Medicine Research·Andrés Jagua-GualdrónRoger Edwin Fernadez-Bernal

❮ Previous
Next ❯

Software Mentioned

GraphPad Prism

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Related Papers

European Annals of Allergy and Clinical Immunology
M C Pereira SantosA G Palma Carlos
Journal of Investigational Allergology & Clinical Immunology
R Lang, Thomas Hawranek
Allergologia et immunopathologia
L Sánchez-MorillasA R Domínguez Lázaro
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
Mitja Kosnik, Peter Korosec
© 2022 Meta ULC. All rights reserved